# 225Ac/64Cu-PD-29875 (Claudin 18.2)

Source: https://onco.cc/drugs/pd-29875/  
OnCo record `pd-29875` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

225Ac/64Cu-PD-29875 (Claudin 18.2) is an experimental radioligand peptide-drug conjugate from PeptiDream, in preclinical development for gastric cancer.

## Summary

225Ac/64Cu-PD-29875 (Claudin 18.2) (PD-29875) is a radioligand peptide-drug conjugate (RI-PDC) from PeptiDream. A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer. Its furthest stage is preclinical development, for gastric cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline lists IND-enabling for both therapeutic and diagnostic. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Also known as: PD-29875
- Tags: pipeline
- Code: PD-29875
- Modality: Radioligand peptide-drug conjugate (RI-PDC)
- Mechanism: A peptide-radioisotope conjugate against Claudin 18.2, for diagnosis and treatment of gastric cancer.

## Sources

- PeptiDream: peptidream.com: https://www.peptidream.com/en/pipeline/
- PeptiDream: peptidream.com: https://www.peptidream.com/en/pipeline/

## Connected records

- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [PeptiDream](https://onco.cc/companies/peptidream/)

---
JSON: https://onco.cc/api/v1/entities/pd-29875.json